Filana Therapeutics, Inc. reported a net loss of $91 million for 2025, significantly higher than the previous year's loss of $24.3 million. The company is focusing on advancing its TSC-related epilepsy program while managing cash efficiently, with $95.5 million reported at year-end.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.